Sanjeev Anant Kulkarni

USPTO Granted Patents = 15 (Patent Applications = 3)

CIPO Patents = 2 (Patent Applications = 2)

EPO Patents = 4 (Patent Applications = 7)

Average Co-Inventor Count = 8.9

ph-index = 2

Forward Citations = 15(Granted Patents)

Location History:

Maharashtra, IN (2016)
Pune, IN (2015 - 2024)

Company Filing History:

Lupin Atlantis Holdings Sa

Years Active: 2015-2024

Loading Chart...

15 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 11952380 - Substituted bicyclic heterocyclic compounds as PRMT5 inhibitors (2024-04-09),

2. 11459330 - Substituted bicyclic heterocyclic compounds as PRMT5 inhibitors (2022-10-04),

3. 9987249 - Substituted chroman compounds as calcium sensing receptor modulators (2018-06-05),

4. 9944639 - Quinolizinone derivatives as PI3K inhibitors (2018-04-17),

5. 9908880 - Substituted imidazoquinolines (2018-03-06),

6. 9598391 - Substituted chroman compounds as calcium sensing receptor modulators (2017-03-21),

7. 9598371 - Arylalkylamine compounds as calcium sensing receptor modulators (2017-03-21),

8. 9493396 - Substituted naphthalene compounds as calcium sensing receptor modulators (2016-11-15),

9. 9464063 - Benzo [B] [1,4] oxazin derivatives as calcium sensing receptor modulators (2016-10-11),

10. 9446040 - Substituted imidazoquinolines (2016-09-20),

11. 9382216 - Substituted morpholines as modulators for the calcium sensing receptor (2016-07-05),

12. 9227919 - Arylalkylamine compounds as calcium sensing receptor modulators (2016-01-05),

13. 9163001 - Substituted chroman compounds as calcium sensing receptor modulators (2015-10-20),

14. 9073913 - Substituted imidazoquinolines (2015-07-07),

15. 9006442 - Cannabinoid receptor modulators (2015-04-14),

Title: Sanjeev Anant Kulkarni: Innovator in Pharmaceutical Compounds

Introduction: Sanjeev Anant Kulkarni, an esteemed inventor based in Pune, India, has made significant contributions to the field of pharmaceuticals. With a total of 15 patents to his name, Kulkarni is recognized for his innovative work that focuses on treating diseases related to the overexpression of certain enzymes.

Latest Patents: Among his latest inventions, Kulkarni has developed substituted bicyclic heterocyclic compounds designed as PRMT5 inhibitors. These compounds include pharmaceutically acceptable salts and compositions aimed at treating various diseases, disorders, or conditions linked to the overexpression of the PRMT5 enzyme. His efforts in this area highlight the potential of these compounds in developing effective treatments for patients suffering from related health issues.

Career Highlights: Sanjeev Anant Kulkarni has had a notable career, working with prominent pharmaceutical companies such as Lupin, Inc. and Lupin Atlantis Holdings SA. His expertise and dedication to innovation have allowed him to carve out a significant place in the industry, contributing to advancements in therapeutic solutions.

Collaborations: Throughout his career, Kulkarni has collaborated with talented professionals, including Venkata Poornapragnacharyulu Palle and Rajender Kumar Kamboj. These collaborations have enriched his research and development endeavors, fostering an environment of creativity and innovation in pharmaceutical science.

Conclusion: In conclusion, Sanjeev Anant Kulkarni stands out as a pioneering inventor in the field of pharmaceutical compounds. With his extensive patent portfolio and commitment to enhancing healthcare through innovative solutions, he continues to make a lasting impact in the industry. His work not only exemplifies the spirit of innovation but also opens new pathways for advancements in medical treatments.

This text is generated by artificial intelligence and may not be accurate.